Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB9 | P28065 | 12/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 5/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7953237 | 0.86 | PSMB9 (0.35) | PSMB9CYP2C9CYP2C19MAPTPSMB8 | |
| SCHEMBL12468417 | 0.83 | PSMB9 (0.36) | PSMB9CYP2C9CYP2C19MAPTPSMB8 | |
| SCHEMBL12467641 | 0.83 | PSMB9 (0.36) | PSMB9CYP2C9CYP2C19MAPTPSMB8 | |
| SCHEMBL15849570 | 0.83 | PSMB9 (0.36) | PSMB9CYP2C9CYP2C19MAPTPSMB8 | |
| SCHEMBL4304535 | 0.80 | PSMB9 (0.41) | PSMB9PSMB8 | |
| SCHEMBL12472519 | 0.77 | PSMB9 (0.35) | PSMB9CYP2C19MAPTPSMB8HDAC4 | |
| SCHEMBL16258958 | 0.76 | OPRM1 (0.34) | PSMB9MAPTPSMB8HDAC4HDAC1 | |
| SCHEMBL12468425 | 0.74 | PSMB9 (0.34) | PSMB9PSMB8HDAC4HDAC1 | |
| SCHEMBL8247428 | 0.73 | PSMB9 (0.34) | PSMB9MAPTPSMB8 | |
| SCHEMBL12468519 | 0.72 | PSMB9 (0.34) | PSMB9PSMB8HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110182854-A1 | HCV PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182854-A1 | HCV PROTEASE INHIBITORS | SERPINB1, CTSC, HPN | PSMB9 434/4885CYP2C9 1079/4885CYP2C19 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.